Dietary Supplements & Herbal Medications
The
medical use of plants in their natural and unprocessed form undoubtedly began
when the first intelligent animals noticed that certain food plants altered
particular body functions. While there is a great deal of historical
information about the use of plant-based supplements, there is also much
unreliable information from poorly designed clinical studies that do not
account for randomization errors, confounders, and—most importantly—a placebo
effect that can contribute 30–50% of the observed response. Since the
literature surrounding dietary supplements is evolving and much of it is not
peer-reviewed, it is recommended that reputable evidence-based resources be
used to help guide treatment decisions. An unbiased and regularly updated
compendium of basic and clinical reports regarding botanicals is Pharmacists Letter/Prescribers Letter
Natural MedicinesComprehensive Database (see references). Another
evidence-basedresource is Natural
Standard, which includes an international, multi-disciplinary collaborative
website, http://www.naturalstandard.com.
Unfortunately, the evidence available to these objective and unbiased
evaluators is rarely adequate to permit clear conclusions. As a result, all
statements regarding positive benefits should be regarded as preliminary and
even conclusions regarding safety should be considered tentative at this time.
For
legal purposes, “dietary supplements” are distinguished from “prescription
drugs” derived from plants (morphine, digitalis, atropine, etc) by virtue of
being available without a prescription and, unlike “over-the-counter
medications,” are legally considered dietary supplements rather than drugs.
This distinction eliminates the need for proof of efficacy and safety prior to
marketing and also places the burden of proof on the Food and Drug
Administration (FDA) to prove that a supplement is harmful before its use can
be restricted or removed from the market. Although manufacturers are prohibited
from marketing unsafe or ineffective products, the FDA has met significant
challenges from the supplement industry largely due to the strong lobbying
effort by supplement manufac-turers and the variability in interpretation of
the Dietary Supplement Health and Education Act (DSHEA). DSHEA defines dietary
supplements as vitamins, minerals, herbs or other botanicals, amino acids or
dietary supplements used to supplement the diet by increasing dietary intake,
or concentrates, metabolites, constituents, extracts, or any combination of
these ingredients.
CASE STUDY
A 65-year-old man with a history of coronary artery disease, high cholesterol, type 2 diabetes, and hypertension presents with a question about a dietary supplement. He is in good health, exercises regularly, and eats a low-fat, low-salt diet. His most recent laboratory values show that his low-density lipoprotein (LDL) cholesterol is still slightly above goal at 120 mg/dL (goal < 100 mg/dL) and his hemoglobin A1C is well controlled at 6%. His blood pressureis also well controlled. His medications include simvastatin, metformin, benazepril, and aspirin. He also regularly takes a vitamin B complex supplement and coenzyme Q10. He asks you if taking a garlic supplement could help to bring his LDL cholesterol down to less than 100 mg/dL. What are two rationales for why he might be using a coenzyme Q10 supplement? Are there any supplements that could increase bleeding risk if taken with aspirin?
CASE STUDY ANSWER
Garlic has not been
shown to significantly lower LDL choles-terol. It has been shown to have a
small but significant lower-ing effect on total cholesterol, but only when
dietary controls were not in place. There is limited evidence to suggest that
garlic may lower plaque burden in patients with coronary artery disease (CAD).
It is advisable to monitor blood pressure for 2 weeks after initiating a garlic
supplement since he is on prescription medications for hypertension. This
patient might be using coenzyme Q10 for CAD or hypertension, or because he
takes simvastatin. Current literature does not support a reduced risk of
statin-related myopathy. The data supportingbenefits of coenzyme Q10 in
patients with CAD are prelimi-nary and limited to studies in persons with a
previous myocar-dial infarction. Several of the dietary supplements
reviewed(garlic, ginkgo, and ginseng) have antiplatelet effects that could be
additive with aspirin. If this patient were also taking warfarin, additional
interactions could occur with coenzyme Q10 (vitamin K-like structure), St.
John’s wort (cytochrome P450 1A2, 2C9, 3A4 inducer), and melatonin (in vitro
decreased prothrombin time), leading to a decreased warfarin effect, or with
glucosamine (increased international normalized ratio), leading to an increased
warfarin effect.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.